A randomized, double-blind, placebo-controlled clinical study to investigate efficacy and safety of Nutrify Genie s formula in participants having migraine.

A randomized, double blind, placebo controlled clinical trial to investigate efficacy and safety of Nutrify Genie s formulation in migraine. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/081811

Enrollment

Registered

2025-03-06

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G431- Migraine with aura Health Condition 2: G430- Migraine without aura

Interventions

Intervention1: Nutrify Genes formula for Migraine to be given for 120 days.: Neutraceutical food supplement capsules containing Linalool extract from Coriandrum Sativum, Coenzyme Q10, Riboflavin, Vita

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects diagnosed with migraine accompanied by light and sound sensitivity as well as nausea as per International Classification of Headache Disorders, 3rd Edition (ICHD-3). 2. Subjects who are ready to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Subjects who are not ready to sign the informed consent. 2. Subjects with major systemic diseases such as malignancy, connective tissue disorders, liver, and renal diseases, or any other illness which according to the investigator forbids him/her from participating in this clinical trial. 3. Subjects who are already receiving migraine therapy or have taken migraine therapy in the last 15 days from the date of screening. 4. Subjects who have participated in any clinical study in less than a month before the screening visit. 5. Pregnant or breast-feeding female subjects.

Design outcomes

Primary

Measure	Time frame
1.To compare the total number of migraine days between two groups over the treatment period. 2. To compare the reduction in frequency of migraine attacks. Timepoint: Day 0 (Baseline),Day15 (2 weeks),Day30,Day60,Day90 & Day120	—

Secondary

Measure	Time frame
1. To observe the impact of intervention on migraine-free intervals, evaluating whether it helps prolong the time between episodes & reduces the likelihood of future attacks. 2. To compare the severity of pain based on Visual Analog Scale (VAS) between the two groups. 3. To compare the enhancement of mood between the two groups by using the Brief Mood Introspection Scale (BMIS) 4. Functional Assessment of migraine scale (FAM) Timepoint: Day0 (Baseline),Day15 (2 weeks),Day30,Day60,Day90 & Day120	—

Measure

Time frame

1. To observe the impact of intervention on migraine-free intervals, evaluating whether it helps prolong the time between episodes & reduces the likelihood of future attacks. 2. To compare the severity of pain based on Visual Analog Scale (VAS) between the two groups. 3. To compare the enhancement of mood between the two groups by using the Brief Mood Introspection Scale (BMIS) 4. Functional Assessment of migraine scale (FAM) Timepoint: Day0 (Baseline),Day15 (2 weeks),Day30,Day60,Day90 & Day120

—

Countries

India

Contacts

Public ContactMr Ayan Neogi

Vivforever

ayanneogi@vivforever.in9967968612

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026